Sanofi

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. 

CEO
Olivier Antoine M. Charmeil
CEOOlivier Antoine M. Charmeil
Employees
76,493
Employees76,493
Headquarters
Paris, Ile-de-France
HeadquartersParis, Ile-de-France
Founded
1994
Founded1994
Employees
76,493
Employees76,493

SNY Key Statistics

Market cap
113.70B
Market cap113.70B
Price-Earnings ratio
19.13
Price-Earnings ratio19.13
Dividend yield
3.47%
Dividend yield3.47%
Average volume
3.41M
Average volume3.41M
High today
$47.15
High today$47.15
Low today
$46.14
Low today$46.14
Open price
$46.32
Open price$46.32
Volume
2.21M
Volume2.21M
52 Week high
$56.00
52 Week high$56.00
52 Week low
$43.32
52 Week low$43.32

SNY News

TipRanks 11h
Innate Pharma Posts 2025 Results, Flags H2 2026 CTCL Phase 3 Start Amid Cash Runway to Q3

The latest announcement is out from Innate Pharma SA ( (FR:IPH) ). Innate Pharma on March 26, 2026 reported full-year 2025 results, highlighting pipeline progr...

TipRanks 2d
Sanofi Wins FDA Breakthrough Therapy Status for Venglustat in Type 3 Gaucher Disease

Sanofi ( (SNY) ) has issued an update. On March 18, 2026, Sanofi announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation...

TipRanks 2d
Regeneron, Sanofi get approval for Dupixent to treat bullous pemphigoid in Japan

Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare, or MHLW, in Japan has approved Dupixent for the treatment of adults...

Analyst ratings

71%

of 7 ratings
Buy
71.4%
Hold
28.6%
Sell
0%

More SNY News

TipRanks 6d
Sanofi Advances Early Autoimmune Antibody Program With New Phase 1 Study Update

Sanofi SA (SNY) announced an update on their ongoing clinical study. Sanofi (SNY) is running a Phase 1 basket study called “A Phase 1, Open-label, Multiple Asc...

Seeking Alpha 6d
AstraZeneca, Sanofi expand R&D footprint in China

AstraZeneca (AZN) and Sanofi (SNY) have become the latest drugmakers in the West to expand R&D operations in China, a market with highly sought-after R&D prospe...

AstraZeneca, Sanofi expand R&D footprint in China

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.